2023年1月6日

分享本文分享本文CAR-T細胞療法是一種非常有前途的癌症患者治療方法。這是一種免疫療法，醫生收集免疫細胞，在實驗室中修改它們，並提供它們輕鬆識別和殺死癌細胞的能力。當注入患者體內時，這些細胞會繁殖，並作為“活藥物”留在體內。t細胞是CAR-T細胞療法的支柱。t細胞是我們免疫係統的主力，在引導免疫反應和殺死被病原體感染的細胞方麵發揮著關鍵作用。在CAR-T細胞療法中，從患者身上抽取血液，然後將t細胞分離出來。在實驗室中，一種解除武裝的病毒被用於基因改造t細胞，使其表麵產生嵌合抗原受體(CARs)。一旦注入患者體內，這些car就能使t細胞識別並附著在癌細胞上的抗原上，從而摧毀癌細胞。癌症免疫治療領域的科學進展已導致7種CAR-T細胞療法獲得批準，包括:Kymriah (tisagenlecleucel) Carvykti (Ciltacabtagene autoleucel)而Relma-cel已在中國獲得NMPA批準，其他6種療法均已在美國獲得FDA批準。這些曆史性的批準表明car - t市場已經到來，並正在席卷生物技術行業。這使得CAR-T的投資達到了驚人的新高度。 At first the trend was subtle, but the tide has swelled as CAR-T start-ups have been richly funded by investors eager to get into this expanding area of regenerative medicine. In total, there has been an astonishing $100 billion of market capitalization from CAR-T companies in recent years. Financing rounds by CAR-T companies have approached $4 billion, while CAR-T industry partnerships have contributed an astounding $2 billion. M&A activity has been even more aggressive, with Celgene snagging Juno Therapeutics for $9 billion in 2018 and Bristol-Myers Squibb (BMS) acquiring Celgene for $74B by 2019. Gilead's acquisition of Kite Pharma for $11.9 billion also made waves, as did other transactions, such as Astellas Pharma's acquisition of Xyphos Biosciences and its CAR-T technology for $665 million. The billion-dollar CAR-T cell therapy market would not have been possible without the remarkable efficacy of the early CAR-T therapies in treating several types of blood cancers. Ranging from small start-ups to billion-dollar companies, CAR-T companies are proliferating in all healthcare markets worldwide. This 321-page market report reveals: Global CAR-T cell therapy market size, with segmentation by product, geography, and indication Future market size forecasts by segment through 2030 Detailed coverage of the approved CAR-T products, including regulatory approvals, pricing, reimbursement, and degree of market penetration Clinical trial activity by type, geography, phase, and sponsor Comprehensive CAR-T patent analysis, including top inventors, patent holders, patent types, geographies, and most cited patents CAR-T industry mergers and acquisitions, ipos, and financing events Strategic partnerships, alliances, and co-commercialization agreements within the CAR-T sector Market trends, future directions, and emerging opportunities Profiles of leading CAR-T competitors composing the global marketplace and much more. 2.8.7 Focus on Shortening Hospital Stay 2.8.8 Focus on Discovering New Antigens 2.8.9 Shifting from Autologous to Allogeneic CAR-T Therapies 2.8.10 CAR-T for the Masses 2.8.11 New In Vivo CAR-T Approach 2.8.12 Combination with mRNA Vaccine 2.8.13 Combination with Oncolytic Virus 2.9 Direct Competition between Autologous CAR-T Therapies 3. CAR-T CELL THERAPY: PRODUCT DEVELOPMENT 4. SCALABLE MANUFACTURING OF CAR-T CELLS 4.1 The Manufacturing Process of Clinical-Scale Autologous CAR-T Therapies 4.2 The Evolution of CAR-T Cell Manufacturing Platforms 4.2.1 Open vs. Closed Systems 4.2.2 Manual Processing vs. Automation 4.2.3 Autologous vs. Allogeneic Manufacturing 4.4 Operating Expenses in Autologous CAR-T Manufacturing 4.5 Operating Expenses in Allogeneic CAR-T Manufacturing 5. CAR-T TARGET ANTIGENS